TheEdgeResearch
Home / Stocks / HAVLF

HAVN Life Sciences Inc. (HAVLF)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$2,565
Sector
Healthcare
Industry
Biotechnology
Beta
-0.30
52-Wk Range
0.00001-0.01
CEO
Tim Moore
Country
CA
Currency
USD

HAVN Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Moody, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,565. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -8117.8%. Its beta of -0.30 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.01
Price / Sales
4.17
Price / Book
0.04
EV / EBITDA
-0.02
Gross margin
32.4%
Operating margin
-3548.4%
Net margin
-8117.8%
Return on equity
—
Debt / equity
0.12
Current ratio
4.51
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
6
IPO date
2021-01-08
Headquarters
Port Moody, BC, CA
About HAVN Life Sciences Inc.

HAVN Life Sciences Inc. is a biotechnology firm dedicated to the research and creation of psychotropic compounds sourced from flora and fungi. The company's expertise includes devising standardized and quality-assured extraction techniques for psychoactive substances, particularly from Psilocybe mushrooms, to isolate key compounds such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health remedies using non-regulated ingredients. This Canadian company, founded in 2020, is headquartered in Richmond.

Comparable companies

HAVN Life Sciences Inc. is most often compared with the following Healthcare names:

ADXSARUXFAXIMNRPRPKTXREPCFRGBPSIGYTLISZLDAF
More research on HAVLF
HAVLF technical analysis HAVLF TheEdge Score Compare against peers
Open full interactive analysis & DCF →